MX2021009743A - Derivados de tieno[3,2-b] pirrol[3,2-d]piridazinona y uso de estos como derivados de pkm2 para el tratamiento del cáncer, la obesidad y trastornos relacionados con la diabetes. - Google Patents

Derivados de tieno[3,2-b] pirrol[3,2-d]piridazinona y uso de estos como derivados de pkm2 para el tratamiento del cáncer, la obesidad y trastornos relacionados con la diabetes.

Info

Publication number
MX2021009743A
MX2021009743A MX2021009743A MX2021009743A MX2021009743A MX 2021009743 A MX2021009743 A MX 2021009743A MX 2021009743 A MX2021009743 A MX 2021009743A MX 2021009743 A MX2021009743 A MX 2021009743A MX 2021009743 A MX2021009743 A MX 2021009743A
Authority
MX
Mexico
Prior art keywords
derivatives
sub
pkm2
thieno
pyrrole
Prior art date
Application number
MX2021009743A
Other languages
English (en)
Inventor
Tao Liu
Jingjing Ji
Zhihua Sui
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of MX2021009743A publication Critical patent/MX2021009743A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

En la presente descripción se describen compuestos que regulan la actividad de la piruvato quinasa, composiciones farmacéuticas y métodos de uso de estos. Estos compuestos están representados por la Fórmula (I)(VER FORMULA) (I) en donde R2, L1-L2, U1-U7, m, anillo A, y Q son como se definen en la presentedescripción.
MX2021009743A 2019-02-13 2020-02-12 Derivados de tieno[3,2-b] pirrol[3,2-d]piridazinona y uso de estos como derivados de pkm2 para el tratamiento del cáncer, la obesidad y trastornos relacionados con la diabetes. MX2021009743A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962805040P 2019-02-13 2019-02-13
PCT/US2020/017965 WO2020167976A1 (en) 2019-02-13 2020-02-12 Thieno[3,2-b] pyrrole[3,2-d]pyridazinone derivatives and their use as pkm2 derivatives for the treatment of cancer, obesity and diabetes related disorders

Publications (1)

Publication Number Publication Date
MX2021009743A true MX2021009743A (es) 2021-11-12

Family

ID=69941460

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021009743A MX2021009743A (es) 2019-02-13 2020-02-12 Derivados de tieno[3,2-b] pirrol[3,2-d]piridazinona y uso de estos como derivados de pkm2 para el tratamiento del cáncer, la obesidad y trastornos relacionados con la diabetes.

Country Status (14)

Country Link
US (1) US20220127267A1 (es)
EP (1) EP3924056A1 (es)
JP (1) JP2022520090A (es)
KR (1) KR20210128435A (es)
CN (1) CN113646050A (es)
AU (1) AU2020221837A1 (es)
BR (1) BR112021015996A2 (es)
CA (1) CA3129829A1 (es)
CO (1) CO2021011919A2 (es)
IL (1) IL285445A (es)
MA (1) MA54948A (es)
MX (1) MX2021009743A (es)
SG (1) SG11202108744WA (es)
WO (1) WO2020167976A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111032046B (zh) 2017-08-15 2023-09-26 安吉奥斯医药品有限公司 丙酮酸激酶调节剂及其用途
AU2021311597A1 (en) * 2020-07-21 2023-02-02 The Regents Of The University Of Michigan Compositions and methods for activating pyruvate kinase
WO2022170200A1 (en) 2021-02-08 2022-08-11 Global Blood Therapeutics, Inc. 1-(2-sulfonyl-2,6-dihydropyrrolo[3,4-c]pyrazol-5(4h)-yl]-ethanone derivatives as pyruvate kinase (pkr) and pkm2 activators for the treatment of sickle cell disease
CA3231728A1 (en) 2021-09-30 2023-04-06 Sitryx Therapeutics Limited Novel compounds
TW202325288A (zh) 2021-11-05 2023-07-01 英商喜翠克斯治療有限公司 新穎化合物
CA3238806A1 (en) 2021-12-22 2023-06-29 Sitryx Therapeutics Limited Phthalazine derivatives as pyruvate kinase modulators
CN115487190A (zh) * 2022-11-01 2022-12-20 复旦大学附属中山医院 丙酮酸激酶m2激活剂在制备治疗系统性红斑狼疮的药物中的应用
WO2024095012A1 (en) 2022-11-04 2024-05-10 Sitryx Therapeutics Limited Phthalazine derivatives as pyruvate kinase modulators

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3041868C (en) * 2008-10-09 2023-03-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bis sulfonamide piperazinyl and piperidinyl activators of human pyruvatekinase
IN2012DN00471A (es) 2009-06-29 2015-06-05 Agios Pharmaceuticals Inc
AU2012250690B2 (en) * 2011-05-03 2017-06-08 Agios Pharmaceuticals, Inc Pyruvate kinase activators for use in therapy
RU2675656C2 (ru) * 2011-05-03 2018-12-21 Аджиос Фармасьютикалз, Инк. Способы применения активаторов пируваткиназы
WO2012151450A1 (en) * 2011-05-03 2012-11-08 Agios Pharmaceuticals, Inc. Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia
US9921221B2 (en) 2012-07-26 2018-03-20 Joslin Diabetes Center, Inc. Predicting and treating diabetic complications
CN111032046B (zh) * 2017-08-15 2023-09-26 安吉奥斯医药品有限公司 丙酮酸激酶调节剂及其用途

Also Published As

Publication number Publication date
WO2020167976A1 (en) 2020-08-20
US20220127267A1 (en) 2022-04-28
BR112021015996A2 (pt) 2021-11-09
CO2021011919A2 (es) 2021-12-10
KR20210128435A (ko) 2021-10-26
IL285445A (en) 2021-09-30
AU2020221837A1 (en) 2021-09-02
SG11202108744WA (en) 2021-09-29
MA54948A (fr) 2021-12-22
CA3129829A1 (en) 2020-08-20
CN113646050A (zh) 2021-11-12
JP2022520090A (ja) 2022-03-28
EP3924056A1 (en) 2021-12-22

Similar Documents

Publication Publication Date Title
MX2021009743A (es) Derivados de tieno[3,2-b] pirrol[3,2-d]piridazinona y uso de estos como derivados de pkm2 para el tratamiento del cáncer, la obesidad y trastornos relacionados con la diabetes.
CR20200588A (es) Compuestos novedosos
MX2022008066A (es) Compuestos triciclicos sustituidos.
PH12020551870A1 (en) Tetracyclic heteroaryl compounds
MX2020001776A (es) Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
MX2023010806A (es) 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-onas sustituidas.
MX2021010674A (es) Compuestos triciclicos condensados utiles como agentes anticancerigenos.
ZA202201329B (en) Quinazolin-4-one derivatives useful for the treatment of braf-associated diseases and disorders
CR20220312A (es) Compuestos tricíclicos sustituidos
MXPA06009475A (es) Derivados de quinazolina y usos terapeuticos de los mismos.
EP4104837A3 (en) Heterocyclic compounds as ret kinase inhibitors
WO2019035863A8 (en) PYRUVATE KINASE ACTIVATORS FOR USE IN THE TREATMENT OF HEMATOLOGICAL DISORDERS
RS82804A (en) Glucocorticoid mimetics, methods of making them, pharmaceutical compositions,and uses thereof
WO2005090336A8 (en) 2-propanol and 2-propylamine derivatives and their use as glucocorticoid ligands
TW200633698A (en) Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
MX2023004920A (es) Compuestos inhibidores de la proteina 6 del linfoma de linfocitos b (bcl6).
MX2022015703A (es) Compuestos para el tratamiento de enfermedades y trastornos asociados a braf.
TW200628466A (en) Quinazoline derivatives
PH12020550168A1 (en) Griseofulvin compound and pharmaceutical use thereof
MX2020012058A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cancer.
MX2021007247A (es) Derivados de rapamicina.
MX2020013699A (es) Derivados de pirazol como inhibidores de malt1.
WO2020210320A8 (en) Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones
CR20210014A (es) Derivados de pirrolo [1,2-b] piridazina
TW200635592A (en) Pyridyl-substituted spiro-hydantoin compounds and use thereof